生物技术公司Solid Biosciences宣布,其针对弗里德赖希共济失调研发的SGT-212双通路基因疗法,在首创性1B期Falcon临床试验中已完成对首例受试者的给药。该试验旨在评估这种创新疗法的安全性与初步疗效,标志着公司在该疾病领域的基因治疗探索迈出关键一步。
生物技术公司Solid Biosciences宣布,其针对弗里德赖希共济失调研发的SGT-212双通路基因疗法,在首创性1B期Falcon临床试验中已完成对首例受试者的给药。该试验旨在评估这种创新疗法的安全性与初步疗效,标志着公司在该疾病领域的基因治疗探索迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.